Abstract
The use of adriamycin is frequently limited by the development of a cumulative-dose-dependent cardiomyopathy, which increases substantially in incidence at doses ≥550 mg/m2. To avoid the potential development of fatal refractory congestive heart failure (CHF), dose limitation to 450–550 mg/m2has been recommended by a variety of authors.1–3Since an oncologist may not wish to stop treatment of an individual patient at an arbitrary level, a considerable investment of time and resources has been made in an effort to extend the use of adriamycin or develop analogs with diminished cardiotoxicity to accomplish the same aim.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Minow, R. A., Benjamin, R. S., Lee, E. T., Gottlieb, J. A.: Adriamycin cardiomyopathy: risk factor. Cancer 39: 1397 - 1402.
Lefrak, E.A., Pitha, J., Rosenheim, S., Gottlieb, J.A.: A clinico-pathologic analysis of adriamycin cardiotoxicity, Cancer 32:302- 314, 1973.
Blum, R.H., Carter, S.K.: Adriamycin: A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249 - 259, 1974.
Billingham, M., Bristow, M.R., Glatstein, E., et al: Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Path 1: 17 - 23, 1977.
Bristow, M.R., Mason, J.W., Billingham, M.E., et al: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardical biopsy and cardiac catheterization. Ann Intern Med 88: 169 - 175, 1978.
Mackay, B., Keyes, L.M., Benjamin, R.S., et al: Cardiac biopsy. Texas Society for Electron Microscopy Journal 11: 7 - 15, 1981.
Legha, S.S., Benjamin, R.S., Mackay, B., et al: Reduction of infus ion. Ann Intern Med 96: 133 - 139, 1982.
Valdivieso, M., Burgess, M.A., Ewer, M.S., et al: Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer. A prospective, randomized study. J Clin Oncology 2: 207 - 214, 1984.
Ever, M.S., Ali, M.K., Mackay, B., et al: A comparison of cardiac adriamycin. J Clin Oncology 2: 112 - 117, 1984.
Chawla, S.P., Benjamin, R.S., Legha, S.S., et al: Role of cardiac biopsy and radionuclide scan in monitoring of adriamycin-induced cardiotoxicity in ‘Proceedings of the 13th International Congress of Chemotherapy,’ K.H. Spitzy and K. Karrer, eds., Verlag H. Eger- mann, Vienna, 1983, pp 490 - 492.
Alexander, J., Dainiak, N., Berger, H.J., et al: Serial assessment of angiocardiography. N Engl J Med 300: 278 - 283, 1979.
Weiss, A.J., Manthel, R.W.: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to lack of cardiac toxicity. Cancer 40: 2046 - 2052, 1977.
Chlebowski, R.T., Paroly, W.S., Pugh, R.P., et al: Adriamycin given as weekly schedule without a loading course: clinically effective with a reduced incidence of cardiotoxicity. Cancer Treat Rep 64: 47 - 51, 1980.
Von Hoff, D.D., Layard, M.W., Basas, P., et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710 - 717, 1979.
Torti, F.M., Bristow, M.R., Howes, A.E., et al: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99: 745 - 749, 1983.
Legha, S.S., Benjamin, R.S., Mackay, B., et al: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49: 1763 - 1766, 1982.
Benjamin, R.S.: A practical approach to adriamycin toxicology. Cancer Chemotherap Rep 6: 191 - 194, 1975.
Benjamin, R.S. and Yap, B.S.: Infusion chemotherapy for soft tissue sarcomas. IN: ‘Soft Tissue Sarcomas,’ Baker LH, ed., Martinus Nijhoff, The Netherlands, 1983, pp 345 - 350.
Hortobagyi, G., Frye, D., Blumenschein, G., et al: FAC with adria mycin by continuous infusion for treatment of advanced breast cancer. Proc Am Soc Clin Oncol 2: 105, 1983.
Haq, M.M., Legha, S.S., Choksi, J., et al: Doxorubicin-induced congestive heart failure in adults. Cancer 56: 1361 - 1365, 1985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Plenum Press, New York
About this chapter
Cite this chapter
Benjamin, R.S. et al. (1986). Continuous-Infusion Adriamycin. In: Rosenthal, C.J., Rotman, M. (eds) Clinical Applications of Continuous Infusion Chemotherapy and Concomitant Radiation Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2197-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2197-2_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9291-3
Online ISBN: 978-1-4613-2197-2
eBook Packages: Springer Book Archive